Strata Completes $21.5 Million Acquisition of HLT-NRP
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2026
0mins
Source: Newsfilter
- Acquisition Completed: Strata has successfully acquired Heart and Lung Transplant National Recovery Program (HLT-NRP) for $21.5 million, executed at a mid-single-digit multiple of Adjusted EBITDA, aligning with Strata's capital deployment strategy and expected to significantly enhance its transplant clinical business scale and market share.
- Growth Potential: This acquisition will substantially expand Strata's network of transplant surgeons, particularly in key markets like Florida and California, thereby improving the company's responsiveness and service quality in transplant services, which is likely to enhance customer satisfaction and competitive positioning.
- Financial Performance Outlook: HLT-NRP is projected to generate approximately $10 million in revenue and $3.1 million in Adjusted EBITDA for 2026, further driving Strata's overall financial performance and supporting the company's long-term profitability goals.
- Strategic Integration Benefits: By integrating HLT-NRP, Strata can efficiently leverage its experienced transplant recovery surgeons while maintaining high clinical service standards, which is expected to provide robust support for the company's future growth and market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRTA
Wall Street analysts forecast SRTA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.240
Low
8.00
Averages
9.63
High
11.25
Current: 5.240
Low
8.00
Averages
9.63
High
11.25
About SRTA
Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient. Its other clinical services include cardiac care and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strata Completes $21.5 Million Acquisition of HLT-NRP
- Acquisition Completed: Strata has successfully acquired Heart and Lung Transplant National Recovery Program (HLT-NRP) for $21.5 million, executed at a mid-single-digit multiple of Adjusted EBITDA, aligning with Strata's capital deployment strategy and expected to significantly enhance its transplant clinical business scale and market share.
- Growth Potential: This acquisition will substantially expand Strata's network of transplant surgeons, particularly in key markets like Florida and California, thereby improving the company's responsiveness and service quality in transplant services, which is likely to enhance customer satisfaction and competitive positioning.
- Financial Performance Outlook: HLT-NRP is projected to generate approximately $10 million in revenue and $3.1 million in Adjusted EBITDA for 2026, further driving Strata's overall financial performance and supporting the company's long-term profitability goals.
- Strategic Integration Benefits: By integrating HLT-NRP, Strata can efficiently leverage its experienced transplant recovery surgeons while maintaining high clinical service standards, which is expected to provide robust support for the company's future growth and market expansion.
See More
Strata Critical Medical Announces Expiration of Warrants
- Warrants Expiration: Strata Critical Medical announced that its Public Warrants (NASDAQ:SRTAW) and Private Placement Warrants expired at 5:00 p.m. ET on May 7, 2026, marking the end of this financing tool and potentially impacting future capital structure.
- Healthcare Service Network: Strata operates one of the largest air transport and surgical services networks in the U.S. healthcare industry, focusing on transplant hospitals and organ procurement organizations, which enhances the efficiency of organ recovery processes.
- Core Service Integration: The company's core services include air and ground logistics, surgical organ recovery, organ placement, and perfusion staffing and equipment solutions for cardiovascular surgery centers, showcasing its comprehensive capabilities in the medical services sector.
- Brand Strategy: Strata strengthens its market position in the transplant industry through its Trinity Medical Solutions and Keystone Perfusion brands, aiming to enhance customer satisfaction and competitive edge by integrating resources.
See More
Strata Critical Medical Reports Strong Q1 2026 Earnings with 87% Revenue Growth
- Significant Revenue Growth: Strata Critical Medical reported an impressive 87.4% year-over-year revenue increase in Q1 2026, reaching $67.4 million, with Logistics revenue rising 32.4% to $47.6 million, demonstrating the company's strong market performance and business expansion capabilities.
- Cash Flow Improvement: The company generated $3.9 million in operating cash flow and $2.1 million in free cash flow this quarter, marking a significant enhancement in cash generation capacity before aircraft acquisitions, with expectations for further improvements in earnings quality and cash conversion in upcoming quarters.
- Acquisition Strategy Advancement: The announcement of the $1 million acquisition of Ohio Valley Perfusion Associates is expected to contribute approximately $100,000 of adjusted EBITDA for the remainder of the year, showcasing the company's proactive approach to M&A and financial flexibility.
- Stable Outlook: Management reiterated its 2026 revenue guidance of $260 million to $275 million and adjusted EBITDA of $29 million to $33 million, maintaining confidence in future performance despite challenges from fuel price volatility and market demand fluctuations.
See More
Blade Air Mobility Q1 Earnings Exceed Expectations
- Earnings Beat: Blade Air Mobility reported a Q1 GAAP EPS of $0.03, exceeding expectations by $0.07, which indicates a significant improvement in profitability and boosts investor confidence.
- Strong Revenue Growth: Q1 revenue reached $67.4 million, a 24.1% year-over-year increase, surpassing market expectations by $3.73 million, reflecting the company's competitive edge and growth potential in the market.
- Logistics Performance: Logistics revenue and gross profit grew by 32.4% and 29.9% year-over-year, respectively, showcasing Strata's robust organic growth and solidifying its market position in medical logistics.
- Adjusted EBITDA Growth: Q1 adjusted EBITDA was $6.4 million with a net income of $2.4 million, indicating profitability in ongoing operations and strengthening the financial foundation for future expansion.
See More
Blade Air Mobility to Announce Q1 Earnings on May 6
- Earnings Announcement: Blade Air Mobility (SRTA) is set to announce its Q1 2023 earnings on May 6 before market open, with a consensus EPS estimate of -$0.04, indicating ongoing challenges in profitability.
- Revenue Growth Expectations: Analysts project Blade Air Mobility's revenue to reach $63.67 million, reflecting a 17.3% year-over-year increase, suggesting potential sales growth in the market despite the anticipated losses.
- Strategic Expansion: Strata Critical Medical (SRTA) has raised its 2026 revenue guidance to between $260 million and $275 million, driven by 35% organic growth, showcasing the success of its acquisition strategy and strong market demand.
- Stock Price Reaction: Strata Critical Medical's stock surged by 21% following its Q4 earnings report, indicating investor optimism regarding its revenue growth and future prospects.
See More
Strata Critical Medical to Present at Needham Conference
- Conference Announcement: Strata Critical Medical will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 1:30 PM ET, showcasing its latest advancements in medical logistics, which is expected to attract investor and industry attention.
- Webcast Availability: The event will feature a webcast accessible through the company's investor relations section, ensuring transparency and enhancing engagement with investors, thereby improving the company's public image.
- Business Expansion: Strata Critical Medical is strategically expanding its service portfolio through acquisitions and organic growth, particularly highlighting its subsidiary Trinity Medical Solutions' leadership in organ transportation, demonstrating the company's strong competitive position in the healthcare services market.
- Forward-Looking Statements: The press release includes forward-looking statements that emphasize future growth opportunities and potential risks, indicating management's confidence in the company's future while also cautioning investors to consider external factors that may impact performance.
See More
Strata Completes $21.5 Million Acquisition of HLT-NRP
- Acquisition Completed: Strata has successfully acquired Heart and Lung Transplant National Recovery Program (HLT-NRP) for $21.5 million, executed at a mid-single-digit multiple of Adjusted EBITDA, aligning with Strata's capital deployment strategy and expected to significantly enhance its transplant clinical business scale and market share.
- Growth Potential: This acquisition will substantially expand Strata's network of transplant surgeons, particularly in key markets like Florida and California, thereby improving the company's responsiveness and service quality in transplant services, which is likely to enhance customer satisfaction and competitive positioning.
- Financial Performance Outlook: HLT-NRP is projected to generate approximately $10 million in revenue and $3.1 million in Adjusted EBITDA for 2026, further driving Strata's overall financial performance and supporting the company's long-term profitability goals.
- Strategic Integration Benefits: By integrating HLT-NRP, Strata can efficiently leverage its experienced transplant recovery surgeons while maintaining high clinical service standards, which is expected to provide robust support for the company's future growth and market expansion.
See More
Strata Critical Medical Announces Expiration of Warrants
- Warrants Expiration: Strata Critical Medical announced that its Public Warrants (NASDAQ:SRTAW) and Private Placement Warrants expired at 5:00 p.m. ET on May 7, 2026, marking the end of this financing tool and potentially impacting future capital structure.
- Healthcare Service Network: Strata operates one of the largest air transport and surgical services networks in the U.S. healthcare industry, focusing on transplant hospitals and organ procurement organizations, which enhances the efficiency of organ recovery processes.
- Core Service Integration: The company's core services include air and ground logistics, surgical organ recovery, organ placement, and perfusion staffing and equipment solutions for cardiovascular surgery centers, showcasing its comprehensive capabilities in the medical services sector.
- Brand Strategy: Strata strengthens its market position in the transplant industry through its Trinity Medical Solutions and Keystone Perfusion brands, aiming to enhance customer satisfaction and competitive edge by integrating resources.
See More
Strata Critical Medical Reports Strong Q1 2026 Earnings with 87% Revenue Growth
- Significant Revenue Growth: Strata Critical Medical reported an impressive 87.4% year-over-year revenue increase in Q1 2026, reaching $67.4 million, with Logistics revenue rising 32.4% to $47.6 million, demonstrating the company's strong market performance and business expansion capabilities.
- Cash Flow Improvement: The company generated $3.9 million in operating cash flow and $2.1 million in free cash flow this quarter, marking a significant enhancement in cash generation capacity before aircraft acquisitions, with expectations for further improvements in earnings quality and cash conversion in upcoming quarters.
- Acquisition Strategy Advancement: The announcement of the $1 million acquisition of Ohio Valley Perfusion Associates is expected to contribute approximately $100,000 of adjusted EBITDA for the remainder of the year, showcasing the company's proactive approach to M&A and financial flexibility.
- Stable Outlook: Management reiterated its 2026 revenue guidance of $260 million to $275 million and adjusted EBITDA of $29 million to $33 million, maintaining confidence in future performance despite challenges from fuel price volatility and market demand fluctuations.
See More
Blade Air Mobility Q1 Earnings Exceed Expectations
- Earnings Beat: Blade Air Mobility reported a Q1 GAAP EPS of $0.03, exceeding expectations by $0.07, which indicates a significant improvement in profitability and boosts investor confidence.
- Strong Revenue Growth: Q1 revenue reached $67.4 million, a 24.1% year-over-year increase, surpassing market expectations by $3.73 million, reflecting the company's competitive edge and growth potential in the market.
- Logistics Performance: Logistics revenue and gross profit grew by 32.4% and 29.9% year-over-year, respectively, showcasing Strata's robust organic growth and solidifying its market position in medical logistics.
- Adjusted EBITDA Growth: Q1 adjusted EBITDA was $6.4 million with a net income of $2.4 million, indicating profitability in ongoing operations and strengthening the financial foundation for future expansion.
See More
Blade Air Mobility to Announce Q1 Earnings on May 6
- Earnings Announcement: Blade Air Mobility (SRTA) is set to announce its Q1 2023 earnings on May 6 before market open, with a consensus EPS estimate of -$0.04, indicating ongoing challenges in profitability.
- Revenue Growth Expectations: Analysts project Blade Air Mobility's revenue to reach $63.67 million, reflecting a 17.3% year-over-year increase, suggesting potential sales growth in the market despite the anticipated losses.
- Strategic Expansion: Strata Critical Medical (SRTA) has raised its 2026 revenue guidance to between $260 million and $275 million, driven by 35% organic growth, showcasing the success of its acquisition strategy and strong market demand.
- Stock Price Reaction: Strata Critical Medical's stock surged by 21% following its Q4 earnings report, indicating investor optimism regarding its revenue growth and future prospects.
See More
Strata Critical Medical to Present at Needham Conference
- Conference Announcement: Strata Critical Medical will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 1:30 PM ET, showcasing its latest advancements in medical logistics, which is expected to attract investor and industry attention.
- Webcast Availability: The event will feature a webcast accessible through the company's investor relations section, ensuring transparency and enhancing engagement with investors, thereby improving the company's public image.
- Business Expansion: Strata Critical Medical is strategically expanding its service portfolio through acquisitions and organic growth, particularly highlighting its subsidiary Trinity Medical Solutions' leadership in organ transportation, demonstrating the company's strong competitive position in the healthcare services market.
- Forward-Looking Statements: The press release includes forward-looking statements that emphasize future growth opportunities and potential risks, indicating management's confidence in the company's future while also cautioning investors to consider external factors that may impact performance.
See More
